The metabolic consequences of gastrointestinal surgery

Cambridge University Hospitals NHS Foundation Trust0 个研究点目标入组 200 人开始时间: 2017年2月3日最近更新: 2020年2月3日

试验速览

暂无简介。

•1. Aged 18 years and over
•2. Capacity to give voluntary informed consent
•3. Undergone, or have planned within the next 12 months, surgery including removal of all or part of the stomach or oesophagus; or be a carrier of a genetic mutation conferring a high risk of requiring a future prophylactic gastrectomy

•All participants:
•1. Aged under 18 years
•2. Recent history of untreated anaemia
•3. Lack capacity to read and retain information about the study
•4. Communication issues which prevent accurate understanding of the study rationale and requirements
•Post-operative participants:
•1. Recurrent gastric or oesophageal cancer
•Participants for endoscopy:
•1. Contraindication to upper gastrointestinal endoscopy
•2. Taking medication that would pose a significant risk of haemorrhage after biopsy (e.g. Clopidogrel, Warfarin, Dipyridamole, novel oral antigoagulants, therapeutic dose heparin)
•3. Significant medical comorbidity that may be adversely effected by endoscopy or sedation (e.g. unstable ischaemic heart disease, significant respiratory impairment)
•Participants for physiological challenge with antibiotics or Somatostatin analogue:
•1. Known allergy to the proposed agent
•2. Received a course of antibiotics in the preceding two months
•3. Suffer from a known illness that may be exacerbated by the proposed agent
•4. Be on medication which interacts with the proposed agent

发起方